Neogenomics (NEO) EBIT (2010 - 2026)

Neogenomics has reported EBIT for 17 years, with the latest figure at -$18.2 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT rose 34.44% year-over-year to -$18.2 million; the trailing twelve-month figure through Mar 2026 stood at -$106.3 million (down 18.95% YoY), and the FY2025 full-year result was -$115.9 million, down 25.81% from the prior year.
• EBIT for Q1 2026 stood at -$18.2 million, down from -$13.4 million in the prior quarter.
• The five-year high for EBIT was -$13.4 million in Q4 2025, with the low at -$52.0 million in Q1 2022.
• Historically, EBIT has averaged -$28.9 million across 5 years, with a median of -$27.0 million in 2025.
• Annual changes were most pronounced in 2022 — EBIT slumped 244.4% — and 2023, when it soared 38.76%.
• Neogenomics' EBIT stood at -$26.4 million in 2022, then grew by 29.6% to -$18.6 million in 2023, then grew by 0.93% to -$18.4 million in 2024, then grew by 27.1% to -$13.4 million in 2025, then tumbled by 35.98% to -$18.2 million in 2026.
• The last three EBIT figures came in at -$18.2 million (Q1 2026), -$13.4 million (Q4 2025), and -$27.0 million (Q3 2025), per Business Quant data.